ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,564.41
1.08%
US Tech 100
19,286.40
-0.10%
Dow Jones
40,415.44
0.32%
Brent Oil
81.42
-0.12%
Bitcoin
66,927.58
-1.00%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Kintara Therapeutics Inc (KTRA)

  7. Kintara Therapeutics Inc (KTRA) News

KTRA

Kintara Therapeutics (KTRA)

Kintara Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:KTRA
DateTimeSourceHeadlineSymbolCompany
07/19/20245:03PMEdgar (US Regulatory)Form S-4/A - Registration of securities, business combinations: [Amend]NASDAQ:KTRAKintara Therapeutics Inc
07/12/20245:17PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTRAKintara Therapeutics Inc
07/08/20246:45AMEdgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:KTRAKintara Therapeutics Inc
07/08/20246:40AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTRAKintara Therapeutics Inc
07/08/20246:30AMPR Newswire (US)TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint InhibitorNASDAQ:KTRAKintara Therapeutics Inc
07/01/20248:35AMPR Newswire (US)Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term MilestonesNASDAQ:KTRAKintara Therapeutics Inc
06/13/20244:10PMEdgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:KTRAKintara Therapeutics Inc
06/13/20244:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTRAKintara Therapeutics Inc
06/03/20248:50AMEdgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:KTRAKintara Therapeutics Inc
06/03/20248:45AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTRAKintara Therapeutics Inc
06/03/20248:35AMPR Newswire (US)TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)NASDAQ:KTRAKintara Therapeutics Inc
05/17/20244:10PMEdgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:KTRAKintara Therapeutics Inc
05/17/20244:05PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:KTRAKintara Therapeutics Inc
05/14/20244:55PMEdgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:KTRAKintara Therapeutics Inc
05/14/20244:50PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTRAKintara Therapeutics Inc
05/14/20244:45PMPR Newswire (US)Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial ResultsNASDAQ:KTRAKintara Therapeutics Inc
05/14/20244:40PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KTRAKintara Therapeutics Inc
05/13/20244:06PMEdgar (US Regulatory)Form S-4 - Registration of securities, business combinationsNASDAQ:KTRAKintara Therapeutics Inc
04/05/20241:09PMPR Newswire (US)Kuehn Law Encourages KTRA, ABIO, SWAV, and NS Investors to Contact Law FirmNASDAQ:KTRAKintara Therapeutics Inc
04/03/20247:00AMPR Newswire (US)Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger AgreementNASDAQ:KTRAKintara Therapeutics Inc
03/27/20249:00AMPR Newswire (US)Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on PembrolizumabNASDAQ:KTRAKintara Therapeutics Inc
02/27/20246:59AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTRAKintara Therapeutics Inc
02/26/20247:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTRAKintara Therapeutics Inc
02/22/20247:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTRAKintara Therapeutics Inc
02/14/20244:07PMPR Newswire (US)Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate UpdateNASDAQ:KTRAKintara Therapeutics Inc
02/12/20249:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTRAKintara Therapeutics Inc
02/12/20249:00AMPR Newswire (US)Kintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast CancerNASDAQ:KTRAKintara Therapeutics Inc
12/18/20234:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTRAKintara Therapeutics Inc
12/18/20234:05PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:KTRAKintara Therapeutics Inc
12/15/20234:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTRAKintara Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:KTRA

Your Recent History

USOTC
ITUP
Interups (CE)
USOTC
IDVV
International Endeavors (PK)
NYSE
AMC
AMC Entertainment
USOTC
MGON
Megola (PK)
USOTC
AABB
Asia Broadband (PK)
USOTC
GRLT
Grillit (PK)
USOTC
SHMP
NaturalShrimp (QB)
USOTC
ECSL
Ecare Solutions (PK)
USOTC
CNNA
Cann American (CE)
USOTC
NBRI
North Bay Resources (PK)
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
NASDAQ
LWLG
Lightwave Logic
USOTC
HIRU
Hiru (PK)
USOTC
CGAC
Code Green Apparel (PK)
USOTC
ELTP
Elite Pharmaceuticals (QB)
USOTC
VPLM
Voip Pal Com (QB)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved